Related references
Note: Only part of the references are listed.Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions
Ben Gold et al.
ACS INFECTIOUS DISEASES (2022)
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update
Fuad Mirzayev et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
Current and future treatments for tuberculosis
Anthony Lee et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Ertapenem and Faropenem againstMycobacterium tuberculosis: in vitro testing and comparison by macro and microdilution
Ximena Gonzalo et al.
BMC MICROBIOLOGY (2020)
Multicenter evaluation of the biochip assay for rapid detection of mycobacterial isolates in smear-positive specimens
Hong Fang et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2019)
Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial
Jung-Kyu Lee et al.
LANCET INFECTIOUS DISEASES (2019)
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
Marjorie Z. Imperial et al.
NATURE MEDICINE (2018)
Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial
Meera Gurumurthy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
Payam Nahid et al.
CLINICAL INFECTIOUS DISEASES (2016)
β-Lactams against Tuberculosis - New Trick for an Old Dog?
Andreas H. Diacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Combinations of beta-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection
Joaquin Rullas et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Hydrolysis of Clavulanate by Mycobacterium tuberculosis β-Lactamase BlaC Harboring a Canonical SDN Motif
Daria Soroka et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus
Amit Kaushik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Rapid Cytolysis of Mycobacterium tuberculosis by Faropenem, an Orally Bioavailable β-Lactam Antibiotic
Neeraj Dhar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis
Corinne S. Merle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
Stephen H. Gillespie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
In Vitro and In Vivo Efficacy of β-Lactams against Replicating and Slowly Growing/Nonreplicating Mycobacterium tuberculosis
Suresh Solapure et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Meropenem-Clavulanic Acid Shows Activity against Mycobacterium tuberculosis In Vivo
Kathleen England et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Targeting Persisters for Tuberculosis Control
Ying Zhang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Letting Sleeping dos Lie: Does Dormancy Play a Role in Tuberculosis?
Michael C. Chao et al.
ANNUAL REVIEW OF MICROBIOLOGY, VOL 64, 2010 (2010)
Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis
Jean-Emmanuel Hugonnet et al.
SCIENCE (2009)
Risk factors for ethambutol optic toxicity
Katherine Anne Talbert Estlin et al.
INTERNATIONAL OPHTHALMOLOGY (2009)
Faropenem medoxomil
Jacob P. Gettig et al.
ANNALS OF PHARMACOTHERAPY (2008)
Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: Focus on faropenem
JMT Hamilton-Miller
PHARMACOTHERAPY (2003)
Share Paper
